{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:12:07Z","timestamp":1788505927234,"version":"build-2803163510"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>The growing interest in deprescribing drugs highlights the importance of re-evaluating prescriptions, but also of limiting inappropriate prescribing. This paper reflects on the ethical use of a placebo as a way of limiting inappropriate prescribing. We focus on psychotropic drugs, but our reasoning may also concern other medical conditions. We analyze the conditions in which placebos are usually prescribed in medicine and analyze four situations to determine which would be best ethical. Although the use of placebos, whether pure (i.e., containing no active substance) or impure (i.e., containing active substances but used in a non-specific manner), is commonplace in medicine, patients are not duly informed: this practice respects neither patient autonomy nor freedom of choice. In contrast, the use of open-label placebos (i.e., prescribed to the patient in full transparency) solves this ethical problem. Importantly, informing the patient about the placebo does not seem to alter its therapeutic effect. Furthermore, the information given to the patient as part of the shared-medical decision generally does not mention the benefits that a placebo could bring to the patient in place of a pharmacologically active drug. However, scientific data on the efficacy of a placebo is available in randomized controlled trials or meta-analyses for almost all drugs. This effect is sometimes high under specific clinical conditions. We conclude that there is an ethical imperative to inform patients of the efficacy of a placebo in a clinical context where the prescription of a pharmacologically active drug is discussed. The open-label placebo option should become more systematic in medicine, particularly in psychological symptoms or conditions with a well-documented significant placebo effect. Aside from this ethical aspect, prescribing more placebos could be a way of combating overprescription, reducing inappropriate drug use and iatrogenia, and supporting the eco-responsible approach to prescribing in medicine.<\/jats:p>","DOI":"10.1177\/20451253261436150","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:56:09Z","timestamp":1788166569000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Informing the patient of the placebo option: an ethical necessity likely to reduce inappropriate psychotropic prescriptions?"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6118-0629","authenticated-orcid":false,"given":"Fabrice","family":"Berna","sequence":"first","affiliation":[{"name":"University of Strasbourg, University Hospitals of Strasbourg, Inserm U1329, 1 place de l\u2019H\u00f4pital, Strasbourg 67091, France"},{"name":"Coll\u00e8ge Universitaire des M\u00e9decines Int\u00e9grative et Compl\u00e9mentaires, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6625-6223","authenticated-orcid":false,"given":"Guillaume","family":"Durand","sequence":"additional","affiliation":[{"name":"Centre Atlantique de PHIlosophie, UR 7463, Nantes Universit\u00e9, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-3186","authenticated-orcid":false,"given":"R\u00e9my","family":"Boussageon","sequence":"additional","affiliation":[{"name":"University of Lyon 1, CNRS UMR 5558, LBBE, EMET, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-8628","authenticated-orcid":false,"given":"Julien","family":"Nizard","sequence":"additional","affiliation":[{"name":"University of Nantes, CHU de Nantes, Service Douleur Soins de Support, \u00c9thique clinique et M\u00e9decine int\u00e9grative, Nantes, France"},{"name":"UMRS INSERM-Nantes Universit\u00e9-Oniris 1229-RMeS, Regenerative Medicine and Skeleton, Nantes, France"},{"name":"Coll\u00e8ge Universitaire des M\u00e9decines Int\u00e9grative et Compl\u00e9mentaires, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Paille","sequence":"additional","affiliation":[{"name":"University of Lorraine, Nancy, France"},{"name":"Coll\u00e8ge Universitaire des M\u00e9decines Int\u00e9grative et Compl\u00e9mentaires, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9843-9999","authenticated-orcid":false,"given":"Laurence","family":"Verneuil","sequence":"additional","affiliation":[{"name":"Inserm U1153, Statistic and Epidemiologic Research Center, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Coll\u00e8ge Universitaire des M\u00e9decines Int\u00e9grative et Compl\u00e9mentaires, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p2730"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119827888"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000381"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-14895-z"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anclin.2024.02.005"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2025.1520664"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202211"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-15"},{"key":"e_1_3_4_11_2","volume-title":"Code of medical ethics of the American Medical Association","author":"American Medical Association","year":"2022","unstructured":"American Medical Association. Code of medical ethics of the American Medical Association. Newburyport: American Medical Association, 2022."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-96425-5"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0994"},{"key":"e_1_3_4_14_2","volume-title":"Principles of biomedical ethics","author":"Beauchamp TL","year":"2019","unstructured":"Beauchamp TL, Childress JF. Principles of biomedical ethics. New York: Oxford University Press, 2019."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1353\/ken.2011.0015"},{"key":"e_1_3_4_16_2","first-page":"75","article-title":"A limited defense of clinical placebo deception","volume":"26","author":"Kolber AJ.","year":"2007","unstructured":"Kolber AJ. A limited defense of clinical placebo deception. Yale Law Policy Rev 2007; 26: 75.","journal-title":"Yale Law Policy Rev"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjhp.12624"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-011012"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2014.13899"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2012-101314"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bioe.12245"},{"key":"e_1_3_4_22_2","article-title":"Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits?","volume":"263","author":"Kaptchuk TJ","year":"2018","unstructured":"Kaptchuk TJ, Miller FG. Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits? BMJ 2018; 263: k3889.","journal-title":"BMJ"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/15265160903318350"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2019-105893"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000003017"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83148-6"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2010.0398"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34790-9"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2011.11.020"},{"key":"e_1_3_4_30_2","volume-title":"Use of placebo in clinical practice","author":"American Medical Agency","year":"2016","unstructured":"American Medical Agency. Use of placebo in clinical practice. In: \u201cPrinciples of Medical Ethics: I,III,V,VIII\u201d, ed. American Medical Association. Chicago: AMA, 2016."},{"key":"e_1_3_4_31_2","unstructured":"General Medical Council. Good medical practice 2024. Manchester: General Medical Council https:\/\/www.gmc-uk.org\/-\/media\/documents\/good-medical-practice-2024\u2014english-102607294.pdf (2024)."},{"key":"e_1_3_4_32_2","volume-title":"Placebo in der Medizin: Herausgegeben von der Bundes\u00e4rztekammer auf Empfehlung ihres Wissenschaftlichen","author":"J\u00fctte R","year":"2010","unstructured":"J\u00fctte R, Hoppe J-D, Scriba PC. Placebo in der Medizin: Herausgegeben von der Bundes\u00e4rztekammer auf Empfehlung ihres Wissenschaftlichen. Bundes\u00e4rztekammer. Berlin: Deutscher \u00c4rzte-Verlag, 2010."},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.banm.2021.07.009","article-title":"Rapport 21-09. La relation m\u00e9decin-malade","volume":"205","author":"Bontoux D","year":"2021","unstructured":"Bontoux D, Autret A, Jaury P, et al. Rapport 21-09. La relation m\u00e9decin-malade. Bulletin de l\u2019Acad\u00e9mie Nationale de M\u00e9decine 2021; 205: 857\u2013866.","journal-title":"Bulletin de l\u2019Acad\u00e9mie Nationale de M\u00e9decine"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067606"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.104"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1214646110"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-016-0177-9"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.022"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/00048670903107575"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077243"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1955.02960340022006"},{"key":"e_1_3_4_42_2","article-title":"Placebo interventions for all clinical conditions","author":"Hr\u00f3bjartsson A","unstructured":"Hr\u00f3bjartsson A, G\u00f8tzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. Epub ahead of print 20 January 2010.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.1994.53"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2023.02.011"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2542-5196(23)00169-9"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.581255"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03074-4"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019101"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-024-00481-y"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/aphw.12444"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0b013e3181e121ed"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.7099"},{"key":"e_1_3_4_53_2","volume-title":"Redefining health care: creating value-based competition on results","author":"Porter ME","year":"2006","unstructured":"Porter ME, Teisberg EO. Redefining health care: creating value-based competition on results. 1st edn. Boston, Mass: Harvard Business Review Press, 2006.","edition":"1"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261436150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253261436150","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261436150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:17:30Z","timestamp":1788502650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253261436150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"alternative-id":["10.1177\/20451253261436150"],"URL":"https:\/\/doi.org\/10.1177\/20451253261436150","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"20451253261436150"}}